Cargando…

Treatment Options for Pancreatic Neuroendocrine Tumors

The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Akirov, Amit, Larouche, Vincent, Alshehri, Sameerah, Asa, Sylvia L., Ezzat, Shereen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628351/
https://www.ncbi.nlm.nih.gov/pubmed/31207914
http://dx.doi.org/10.3390/cancers11060828
_version_ 1783434939650277376
author Akirov, Amit
Larouche, Vincent
Alshehri, Sameerah
Asa, Sylvia L.
Ezzat, Shereen
author_facet Akirov, Amit
Larouche, Vincent
Alshehri, Sameerah
Asa, Sylvia L.
Ezzat, Shereen
author_sort Akirov, Amit
collection PubMed
description The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy.
format Online
Article
Text
id pubmed-6628351
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66283512019-07-23 Treatment Options for Pancreatic Neuroendocrine Tumors Akirov, Amit Larouche, Vincent Alshehri, Sameerah Asa, Sylvia L. Ezzat, Shereen Cancers (Basel) Review The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy. MDPI 2019-06-14 /pmc/articles/PMC6628351/ /pubmed/31207914 http://dx.doi.org/10.3390/cancers11060828 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Akirov, Amit
Larouche, Vincent
Alshehri, Sameerah
Asa, Sylvia L.
Ezzat, Shereen
Treatment Options for Pancreatic Neuroendocrine Tumors
title Treatment Options for Pancreatic Neuroendocrine Tumors
title_full Treatment Options for Pancreatic Neuroendocrine Tumors
title_fullStr Treatment Options for Pancreatic Neuroendocrine Tumors
title_full_unstemmed Treatment Options for Pancreatic Neuroendocrine Tumors
title_short Treatment Options for Pancreatic Neuroendocrine Tumors
title_sort treatment options for pancreatic neuroendocrine tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628351/
https://www.ncbi.nlm.nih.gov/pubmed/31207914
http://dx.doi.org/10.3390/cancers11060828
work_keys_str_mv AT akirovamit treatmentoptionsforpancreaticneuroendocrinetumors
AT larouchevincent treatmentoptionsforpancreaticneuroendocrinetumors
AT alshehrisameerah treatmentoptionsforpancreaticneuroendocrinetumors
AT asasylvial treatmentoptionsforpancreaticneuroendocrinetumors
AT ezzatshereen treatmentoptionsforpancreaticneuroendocrinetumors